James W. Smithy, MD, MHS

This closing segment focuses on safety and the evolving approach to managing this therapy more thoughtfully.

This segment offers a candid, practical look at what patients can expect when undergoing cellular therapy, from initial evaluation through recovery.

This segment explores why patients with lower disease burden and fewer prior lines of therapy tend to experience better outcomes, and what that means for clinical decision-making.

This segment digs into the key efficacy findings from the real-world analyses and how they measure against the pivotal trial that supported approval.

Real-world studies show TIL therapy drives durable melanoma responses with no new safety concerns, but many patients miss eligibility.

Experts unpack real-world TIL therapy results, who qualifies, and how to sequence lifileucel after immunotherapy or BRAF for metastatic melanoma.